# Filing Detail

Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001628280-20-004486
Filing Date
2020-04-02
Accepted
2020-04-01 19:25:26
Documents
8
Period of Report
2020-05-18
Effectiveness Date
2020-04-02

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEF 14A | sgmo_proxyx2020xdef.htm | DEF 14A | 1528750
2 |  | macraesignaturea02.jpg | GRAPHIC | 28251
3 |  | sgmocdagraphiccashinc01.jpg | GRAPHIC | 99051
4 |  | sgmocdagraphicceo2019a02.jpg | GRAPHIC | 43356
5 |  | sgmocdagraphicfactors.jpg | GRAPHIC | 56944
6 |  | sgmocdagraphicprimarya01.jpg | GRAPHIC | 54098
7 |  | sgmoproxycardp1a01.jpg | GRAPHIC | 195814
8 |  | sgmoproxycardp2a01.jpg | GRAPHIC | 115600
| Complete submission text file | 0001628280-20-004486.txt |  | 2325945

Mailing Address 501 CANAL BLVD POINT RICHMOND TECH CNTR. RICHMOND CA 94804
Business Address 501 CANAL BLVD POINT RICHMOND TECH CNTR. RICHMOND CA 94804 5109706000
SANGAMO THERAPEUTICS, INC (Filer) CIK: 0001001233 (see all company filings)

EIN.: 680359556 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 000-30171 | Film No.: 20767000
SIC: 2836 Biological Products, (No Diagnostic Substances)